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Between 1984 and 2006, 12,959 people with HIV/AIDS
(PWHA) in the Swiss HIV Cohort Study contributed a
total of 73,412 person years of follow-up, 35,551 of
which derived from PWHA treated with highly active
antiretroviral therapy (HAART). Out of 597 incidents of
Kaposi sarcoma (KS) identified, 52 were among HAART
users.
Cox regression was used to estimate hazard ratios (HR)
and corresponding 95 percent confidence intervals (CI).
KS incidence fell abruptly from 1996 to 1998 to reach a
plateau at 1.4 per 1000 person years afterwards. Men hav-
ing sex with men (MSM) and birth in Africa or the Middle
East were associated with KS in both non-users and users
of HAART, but the risk pattern by CD4 cell count differed.
Only very low CD4 cell count (<50 cells/ìl) at enrolment
or at HAART initiation were significantly associated with
KS among HAART users. The HR for KS declined steeply in
the first months after HAART initiation and continued to
be low 7 to 10 years afterwards (HR, 0.06; 95% CI, 0.02–
0.17). Out of 52 KS cases among HAART users, 33 out of
52 (63.5%) KS cases among HAART users arose among
PWHA who had stopped treatment or used HAART for
less than 6 months.
from 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical 
Research
Bethesda, MD, USA. 6–7 October 2008
Published: 17 June 2009
Infectious Agents and Cancer 2009, 4(Suppl 2):P17 doi:10.1186/1750-9378-4-S2-P17
<supplement> <title> <p>Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research</p> </title> <sponsor> <note>Publication of this supplement was made possible with support from the Office of HIV and AIDS Malignancy, National Cancer Institute, National Institutes of Health.</note> </sponsor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1750-9378-4-S2-full.pdf">here</a>.</note> url>http://www.biomedcentral.com/content/pdf/1750-9378-4-S2-info.pdf</url> </supplement>
This abstract is available from: http://www.infectagentscancer.com/content/4/S2/P17
© 2009 Franceschi et al; licensee BioMed Central Ltd. 
